| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| S-8 | Securities offered to employees pursuant to employee benefit plans |
Registration Statements
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| DFAN14A | Additional proxy soliciting materials filed by non-management |
Proxy Filings
|
||
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| DFAN14A | Additional proxy soliciting materials filed by non-management |
Proxy Filings
|
||
| SC 13G | A statement of beneficial ownership of common stock by certain persons |
Other
|
||
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| DFAN14A | Additional proxy soliciting materials filed by non-management |
Proxy Filings
|
||
| DFAN14A | Additional proxy soliciting materials filed by non-management |
Proxy Filings
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
